The NRG-LU005 study examined whether adding the immunotherapy drug atezolizumab to standard concurrent chemoradiation could benefit patients with limited-stage small-cell lung cancer. Results presented at the American Society for Radiation Oncology 2024 Annual Meeting showed that adding atezolizumab did not improve overall survival for the patient population.
The trial's primary endpoint analysis found no survival advantage from the immunotherapy addition. However, the twice-daily radiation schedule used in the study was associated with improvements in patient-reported quality of life measures.
